SODIUM IODIDE I 123
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Mar 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
SODIUM IODIDE I 123 by GE HealthCare is clinical pharmacology sodium iodide i-123 is readily absorbed from the upper gastrointestinal tract. First approved in 1976.
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sodium Iodide I-123 is a radioactive diagnostic agent administered orally as a capsule for thyroid imaging and functional assessment. It is absorbed from the gastrointestinal tract, concentrated selectively by the thyroid gland, and used to map thyroid anatomy and detect normal or abnormal tissue function. The iodide accumulation fraction in the thyroid serves as a quantitative measure of thyroid uptake capacity.
LOE Approaching
As a legacy diagnostic product approaching loss of exclusivity with moderate competitive pressure, the brand team is likely small and focused on retention rather than expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Sodium iodide I-123 is readily absorbed from the upper gastrointestinal tract. Following absorption, the iodide is distributed primarily within the extracellular fluid of the body. It is trapped and organically bound by the thyroid and concentrated by the stomach, choroid…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Sodium Iodide I-123 offers limited career advancement opportunity given the product's mature lifecycle and approaching loss of exclusivity. Roles are likely focused on managing decline, maintaining market share, and operational efficiency rather than driving growth or innovation.
Worked on SODIUM IODIDE I 123 at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.